test

Recent Publications

Sznol M, Longo DL.

Release the Hounds! Activating the T-Cell Response to Cancer. 

N Engl J Med. 2014 Dec 6.

Wang J, Chen L.
Myeloid cells' evasion of melanoma immunity.
J Invest Dermatol. 2014 Nov;134(11):2675-7.

Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX.
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Nat Commun. 2014 Oct 28;5:5241.

Lott JP, Wititsuwannakul J, Lee JJ, Ariyan S, Narayan D, Kluger HH, Lazova R.
Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The YaleUniversity Spitzoid Neoplasm Repository experience, 1991 to 2008.
J Am Acad Dermatol. 2014 Oct 9.

Okabe Y, Medzhitov R.
How the immune system spots tumors.
Elife. 2014 Sep 24;3

Lewis JM, Bürgler CD, Fraser JA, Liao H, Golubets K, Kucher CL, Zhao PY, Filler RB, Tigelaar RE, Girardi M.
Mechanisms of Chemical Cooperative Carcinogenesis by Epidermal Langerhans Cells.
J Invest Dermatol. 2014 Sep 18.

Fujiwara H, Maeda Y, Kobayashi K, Nishimori H, Matsuoka K, Fujii N, Kondo E, Tanaka T, Chen L, Azuma M, Yagita H, Tanimoto M.
Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease.
J Immunol. 2014 Sep 1;193(5):2565-73.

Sanmamed MF, Chen L.
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation.
Cancer J. 2014 Jul-Aug;20(4):256-61.

Sehgal K, Ragheb R, Fahmy TM, Dhodapkar MV, Dhodapkar KM.
Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15-Dependent DC Crosstalk.
J Immunol. 2014 Jul 30. pii: 1400489.

Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM.
NY-ESO-1 as a Potential Immunotherapeutic Target in Renal Cell Carcinoma.
Oncotarget. 2014 Jun 13.

Bonasio R, Lecona E, Narendra V, Voigt P, Parisi F, Kluger Y, Reinberg D.
Interactions with RNA direct the Polycomb group protein SCML2 to chromatin where it represses target genes.
Elife. 2014 Jul 1;3:e02637.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.
Targeting CD137 enhances the efficacy of cetuximab.
J Clin Invest. 2014 Jun 2;124(6):2668-82.

Gagliani N, Hu B, Huber S, Elinav E, Flavell RA.
The Fire Within: Microbes Inflame Tumors.
Cell. 2014 May 8;157(4):776-783.

Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM.
MEK targeting in N-RAS mutated metastatic melanoma.
Mol Cancer. 2014 Mar 4;13(1):45

Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, Saito Y, Marches F, Halene S, Palucka AK, Manz MG, Flavell RA.
Development and function of human innate immune cells in a humanized mouse model.
Nat Biotechnol. 2014 Mar 16.

Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV.
Serial exome analysis of disease progression in premalignant gammopathies.
Leukemia. 2014 Feb 5.

Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM.
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.
Cancer Cell Int. 2014 Jan 14;14(1):4.

Parisia, F, Strinoa,F, Nadlerb, B, Kluger, Y.
Ranking and combining multiple predictors without labeled data
PNAS. 2013 Dec 17.

Durazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL.
Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signaling.
Transfus Apher Sci. 2013 Nov 28. 

Crooks M, Seropian S, Bai M, McCorkle R.
Monitoring patient distress and related problems before and after Hematopoietic Stem Cell Transplantation.
Palliat Support Care. 2013 Oct 29:1-9

Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Perry N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B.
Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Blood. 2013 Oct 21.

Sue GR, Lannin DR, Au AF, Narayan D, Chagpar AB.
Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast.
Am J Surg. 2013 Sep 4.

Sznol M, Chen L.
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer--Response.
Clin Cancer Res. 2013 Sep 18.

Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD.
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides.
J Am Acad Dermatol. 2013 Jul

Shahbazian D, Bindra RS, Kluger HM, Glazer PM.
Radiation sensitivity and sensitization in melanoma.
Pigment Cell Melanoma Res. 2013 Jul 2

Chaumeil J, Micsinai M, Ntziachristos P, Roth DB, Aifantis I, Kluger Y, Deriano L, Skok JA.
The RAG2 C-terminus and ATM protect genome integrity by controlling antigen receptor gene cleavage.
Nat Commun. 2013 Jul 31;4:2231.

Strino F, Parisi F, Micsinai M, Kluger Y.
TrAp: a tree approach for fingerprinting subclonal tumor composition.
Nucleic Acids Res. 2013 Jul 27.

Stanton KP, Parisi F, Strino F, Rabin N, Asp P, Kluger Y.
Arpeggio: harmonic compression of ChIP-seq data reveals protein-chromatin interaction signatures.
Nucleic Acids Res. 2013 Jul 19.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M.
Nivolumab plus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2013 Jun 2.

Mitchell KA, Kluger H, Sznol M, Hartman DJ.
Ipilimumab-induced Perforating Colitis.
J Clin Gastroenterol. 2013 Apr 29.

Douglas SR, Longo WE, Narayan D.
A novel technique for perineal hernia repair.
BMJ Case Rep. 2013 Apr 10;2013

Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM.
Advances in therapy for melanoma brain metastases.
Clin Dermatol. 2013 May-Jun;31(3):264-81.

Hoang D, Sue GR, Xu F, Li P, Narayan D.
Absence of aneuploidy and gastrointestinal tumours in a man with a chromosomal 2q13 deletion and BUB1 monoallelic deficiency.
BMJ Case Rep. 2013 Feb 25;2013.

Sznol M, Chen L.
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer.
Clin Cancer Res. 2013 Mar 1;19(5):1021-34.

Chen L, Flies DB.
Molecular mechanisms of T cell co-stimulation and co-inhibition.
Nat Rev Immunol. 2013 Mar 8.

Yao S, Chen L.
Adaptive resistance: a tumor strategy to evade immune attack.
Eur J Immunol. 2013 Feb 4.

Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P.
Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.
Mol Biol Cell. 2013 Feb 6.

Hoang D, Sue GR, Xu F, Li P, Narayan D.
Absence of aneuploidy and gastrointestinal tumours in a man with a chromosomal 2q13 deletion and BUB1 monoallelic deficiency.
BMJ Case Rep. 2013 Feb 25;2013.

Yao S, Chen L.
Adaptive resistance: a tumor strategy to evade immune attack.
Eur J Immunol. 2013 Feb 4.

Leonhardt RM, Vigneron N, Hee JS, Graham M, Cresswell P.
Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.
Mol Biol Cell. 2013 Feb 6.

Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL.
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody.
Clin Cancer Res. 2013 Jan 15;19(2):462-8.

Yao S, Zhu Y, Chen L. 
Advances in targeting cell surface signaling molecules for immune modulation.
Nat Rev Drug Discov. 2013 Feb 1;12(2):130-46. doi: 10.1038/nrd3877.

Dhodapkar M.
Personalized Immune-Interception of Cancer and the Battle of Two Adaptive Systems- When is the Time Right?
Cancer Prev Res (Phila). 2013 Jan 22.

Sznol JA, Jilaveanu LB, Kluger HM.
Studies of NVP-BEZ235 in Melanoma.
Curr Cancer Drug Targets. 2012 Nov 21.

Giesen E, Kluger HM., Thumar J.
Drug targets and predictive biomarkers in the management of metastatic melanoma.
Pharmgenomics Pers Med. 2012;5:139-48

Parker TL, Cooper DL, Seropian SE, Bolognia JL.
Toxic erythema of chemotherapy following i.v. BU plus  fludarabine for allogeneic PBSC transplant.
Bone Marrow Transplant. 2012 Nov 19. doi: 10.1038/bmt.2012.218.

Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W, Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, Flavell RA.
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine.
Nature. 2012 Oct 17.

Parisi F, Micsinai M, Strino F, Ariyan S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y.
Integrated analysis of tumor samples sheds light on tumor heterogeneity.
Yale J Biol Med. 2012 Sep;85(3):347-61.

Prasad S, Cody V, Saucier-Sawyer JK, Fadel TR, Edelson RL, Birchall MA, Hanlon DJ.
Optimization of Stability, Encapsulation, Release, and Cross-Priming of Tumor Antigen-Containing PLGA Nanoparticles.
Pharm Res. 2012 Jul 14.

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Nat Genet. 2012 Jul 29.

Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM.
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.
Nat Mater. 2012 Jul 15.

Li H, Demetris AJ, McNiff J, Matte-Martone C, Tan HS, Rothstein DM, Lakkis FG, Shlomchik WD
Profound Depletion of Host Conventional Dendritic Cells, Plasmacytoid Dendritic Cells, and B Cells Does Not Prevent Graft-versus-Host Disease Induction.
J Immunol. 2012 Mar 14.

Gao Y, Smith E, Ker E, Campbell P, Cheng EC, Zou S, Lin S, Wang L, Halene S, Krause DS.
Role of RhoA-Specific Guanine Exchange Factors in Regulation of Endomitosis in Megakaryocytes.
Dev Cell. 2012 Feb 29.

Jedrych J, Leffell D, McNiff JM.
Desmoplastic trichoepithelioma with perineural involvement: a series of seven cases.
J Cutan Pathol. 2012 Mar;39(3):317-23.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
PLoS One. 2012;7(2):e31331.

Broer N, Buonocore S, Goldberg C, Truini C, Faries MB, Narayan D, Ariyan S.
A proposal for the timing of management of patients with melanoma presenting during pregnancy.
J Surg Oncol. 2012 Feb 13.

Chae, W.-J. and Bothwell, A.L.M. (2011).
IL-17-mediated signaling and intestinal tumorigenesis.  Drug Discovery Today: Disease Mechanisms. 

Teichmann LL, Kashgarian M, Weaver CT, Roers A, Müller W, Shlomchik MJ.
B Cell-Derived IL-10 Does Not Regulate Spontaneous Systemic Autoimmunity in MRL.Faslpr Mice.
J Immunol. 2012 Jan 15;188(2):678-85.

Koduru S, Wong E, Strowig T, Sundaram R, Zhang L, Strout MP, Flavell RA, Schatz DG, Dhodapkar KM, Dhodapkar MV.
Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.
Blood. 2012 Jan 10.

Glusac EJ.
The melanoma 'epidemic': lessons from prostate cancer.
J Cutan Pathol. 2012 Jan;39(1):17-20.

McKay K, McNiff J, Subtil A.
Prominent CD56 expression by damaged and regenerating muscle fibers in the skin.
J Cutan Pathol. 2011 Dec 29. 

Zito C, Kluger HM.
Immunotherapy for metastatic melanoma.
J Cell Biochem. 2011 Oct 17. doi: 10.1002/jcb.23402

Dhodapkar MV, Dhodapkar KM.
Vaccines targeting cancer stem cells: are they within reach?
Cancer J. 2011 Sep;17(5):397-402.

Kluger, H.M., Dudek, A.Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L.B., Molinaro, A., Sznol, M.
A phase 2 trial of dasatinib in advanced melanoma
(2011) Cancer, 117 (10), pp. 2202-2208. Cited 1 time.

Leong, S.P.L., Zuber, M., Ferris, R.L., Kitagawa, Y., Cabanas, R., Levenback, C., Faries, M., Saha, S.
Impact of nodal status and tumor burden in sentinel lymph nodes on the clinical outcomes of cancer patients
(2011) Journal of Surgical Oncology, 103 (6), pp. 518-530.

Kluger, H.M., Hoyt, K., Bacchiocchi, A., Mayer, T., Kirsch, J., Kluger, Y., Sznol, M., Ariyan, S., Molinaro, A., Halaban, R.
Plasma markers for identifying patients with metastatic melanoma
(2011) Clinical Cancer Research, 17 (8), pp. 2417-2425.

Leong, S.P.L., Kim, J., Ross, M., Faries, M., Scoggins, C.R., Metz, W.L.R., Cope, F.O., Orahood, R.C.
A phase 2 study of 99mTc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer
(2011) Annals of Surgical Oncology, 18 (4), pp. 961-969.

Godshalk, S.E., Paranjape, T., Nallur, S., Speed, W., Chan, E., Molinaro, A.M., Bacchiocchi, A., Hoyt, K., Tworkoski, K., Stern, D.F., Sznol, M., Ariyan, S., Lazova, R., Halaban, R., Kidd, K.K., Weidhaas, J.B., Slack, F.J.
A Variant in a MicroRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma
(2011) Oncogene, 30 (13), pp. 1542-1550. Cited 1 time.